Lipella Pharmaceuticals Stock (NASDAQ:LIPO)
Previous Close
$2.41
52W Range
$1.97 - $12.00
50D Avg
$2.78
200D Avg
$3.21
Market Cap
$6.12M
Avg Vol (3M)
$2.17M
Beta
0.31
Div Yield
-
LIPO Company Profile
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.